Zeprumetostat

Phase 2Small molecule

SSun Yat-sen University

Zeprumetostat is one of 97 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaNot yet recruiting

LeukemiaNot yet recruiting

PTCLRecruiting

Peripheral T-Cell Lymphoma (PTCL)Not yet recruiting

Bladder Urothelial CarcinomaRecruiting

LymphomaPhase 2

Not yet recruiting

LeukemiaPhase 1

Not yet recruiting

PTCLPhase 2

Recruiting

Peripheral T-Cell Lymphoma (PTCL)Preclinical

Not yet recruiting

Bladder Urothelial CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zeprumetostat

SSun Yat-sen University

Phase 2

2 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Leukemia

NCT07692529

Q4 2028

Phase 2Not yet recruiting

Gastric Cancer/gastroesophageal Junction Adenocarcinoma

NCT07874425

Q1 2029

Phase 2Recruiting

Bladder Urothelial Carcinoma

NCT07717242

Q3 2029

PreclinicalNot yet recruiting

Peripheral T-Cell Lymphoma (PTCL)

NCT07706959

Phase 2Recruiting

PTCL

NCT07372352

Clinical

Trials by Indication[1]

Lymphoma2 trials

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07339527·60 enrolled

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Recruiting·TTreeline Biosciences, Inc.·Phase 1·NCT07082803·180 enrolled

Not yet recruiting·FFudan University·Phase 2·NCT07874425·55 enrolled

Bladder Urothelial Carcinoma1 trial

Study on Immunotherapy Enhancement Strategies for Muscle-invasive Bladder Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07717242·80 enrolled

1 more indication

Peripheral T-cell Lymphoma (PTCL)1 trial

A New Genotype-guided Therapy in Newly Diagnosed Patients With Peripheral T-cell Lymphoma

Not yet recruiting·RRuijin Hospital·Preclinical·NCT07706959·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Zeprumetostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zeprumetostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zeprumetostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Zeprumetostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Q1 2029

Q3 2029

Trials by Indication[1]

Lymphoma2 trials

PTCL1 trial

Leukemia1 trial

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma1 trial

Bladder Urothelial Carcinoma1 trial

Peripheral T-cell Lymphoma (PTCL)1 trial

References

Drug Info

Quick Facts

Related News